ArtVentive Medical begins testing the Next Generation of its EOS™ Technology

ArtVentive Medical Group, Inc. announced that the Company conducted its first animal study of its next generation of the ArtVentive Endoluminal Occlusion System (EOS™ Gen II). The EOS™ is designed for use in the peripheral vasculature and offers immediate and permanent vessel occlusion in arterial and venous settings.

“This new generation of the ArtVentive EOS™ peripheral device represents a significant step forward in the EOS™ technology and design, offering profile reductions, reversibility, enhanced control over deployment and the opportunity to advance into new indications. These advancements allow for the development of devices of varying diameters – with the ability to treat smaller and larger vessel sizes – necessary to meet growing market demands,” stated Leon Rudakov, PhD, President and CTO of ArtVentive. “The first EOS™ Gen II animal study produced excellent clinical results, demonstrating the safety and effectiveness of this advanced embolization therapy.”